Metrion Biosciences, a Cambridge, UK-based ion channel CRO and drug discovery company, raised £3.7M in funding.
The round was led by Maven Capital Partners, alongside Gresham House Ventures.
The company intends to use the funds to to further expand its laboratories in Cambridge, UK, invest in specialist equipment and enhance global marketing activities.
Metrion Biosciences is a contract research organisation specialising in providing a range of ion channel drug discovery services for its customers. Its approach offers a dedicated, flexible service used to each customer’s requirements. It is supported by rapid reporting and data interpretation by its experienced ion channel team. These services include compound screening assays, detailed characterisation of lead compounds in human cells and native tissue, as well as confirmation of efficacy in stem cell and other phenotypic models.
Metrion also announced the appointment of Dr David Milroy and Steve Carle to the board. At the same time, Dr Marc Rogers, Dr Barry Kenny and Mark Keogh have retired as non-executive directors of the company.
FinSMEs
20/12/2023